2-(4-hydroxyphenyl)ethyl formate

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(4-hydroxyphenyl)ethyl formate
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: RHGCHXDAOUTHJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基苯乙酸甲酯 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 5.0h， 生成 2-(4-hydroxyphenyl)ethyl formate
  参考文献：
  名称：

  在苯酚与氯醛存在下醇的选择性甲酰化

  摘要：

  在环境温度下，在无水K 2 CO 3上与丙酮中的乙二醛搅拌，在苯酚存在下，选择性地使伯醇和仲醇甲酰化，收率很高。

  DOI：

  10.1016/s0040-4020(02)00185-0

文献信息

• COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB
  申请人：Warner-Lambert Company LLC

  公开号：EP1530467A2

  公开（公告）日：2005-05-18
• [EN] COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB<br/>[FR] COMBINAISON D'UN INHIBITEUR CARBOXYLIQUE ALLOSTERIQUE DE METALLOPROTEINASE-13 DE MATRICE ET DE CELECOXIBE OU DE VALDECOXIBE
  申请人：WARNER LAMBERT CO

  公开号：WO2004006912A2

  公开（公告）日：2004-01-22

  This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.
• Selective formylation of alcohols in the presence of phenols with chloral
  作者：Ram N Ram、Nabin Kumar Meher

  DOI：10.1016/s0040-4020(02)00185-0

  日期：2002.4

  Primary and secondary alcohols were formylated selectively in the presence of phenols by stirring with chloral in acetone over anhydrous K2CO3 at ambient temperatures in high yields.

  在环境温度下，在无水K 2 CO 3上与丙酮中的乙二醛搅拌，在苯酚存在下，选择性地使伯醇和仲醇甲酰化，收率很高。